Abstract A146: Study of anti-leukemia activity of N-(1-pyrenlyl) maleimide in vivo using a bioluminescent mouse model

Abstract

Abstract Telomerase plays a pivotal role in cellular immortality and tumorigenesis. Telomerase activity is normally not detectable in most somatic cells, but is activated in the vast majority of cancer cells. Therefore, inhibition of telomerase has been viewed as a promising anticancer approach due to its specificity for cancer cells. During a search for anticancer drugs by screening for small molecules of telomerase inhibitors, we have identified a very promising compound, N-(1-pyrenyl) maleimide, which displays the greatest differential cytotoxicity against hematopoietic Jurkat-T cells in vitro. In this study, we examined the anticancer activity of N-(1-pyrenyl) maleimide against human T-cell acute lymphoblastic leukemia (T-ALL) in vivo. Human T- ALL cells, such as Jurkat cells, were transfected with luciferase-expressing plasmid to establish luciferase-expressing T-ALL cells. The luciferase-expressing T-ALL cells were mixed with matrigel and injected subcutaneously into the nude mice. We have successfully employed such a xenograft method to establish a bioluminescent mouse model for investigating the anti-leukemia activity of N-(1-pyrenyl) maleimide and other classical anti-leukemia drugs. Using the established bioluminescent mouse model, we have begun to examine the anticancer activity of N-(1-pyrenyl) maleimide against T-ALL. We will present our most updated findings in this meeting. (Supported by grant CMRPD3D0171 from Chang Gung Memorial Hospital) Citation Format: Tzu-Chien Wang, Pei-Chi Chang, Chi-Yuan Chen. Study of anti-leukemia activity of N-(1-pyrenlyl) maleimide in vivo using a bioluminescent mouse model. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A146.